AF
IMPL

Amalgamated Financial’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Amalgamated Financial’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$5K Buy
+839
New +$6.34K ﹤0.01% 2965

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's IMPL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q1 2022: 839 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #2965 among its holdings.

42 funds tracked by Wall St. Rank hold IMPL as of Q1 2022.

  • Amalgamated Financial held 839 shares of Impel Pharmaceuticals Inc. Common Stock worth $5K as of Q1 2022.
  • Impel Pharmaceuticals Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
  • Impel Pharmaceuticals Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2965 holding.
  • 42 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.